The molecular bases for Ebola virus replication, pathogenesis and protection.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

This proposal to the MRC will establish a shared, secure, high performance data and compute infrastructure as a platform for large-scale clinical genomics research based on the data flows of the UK 100,000 Genomes project.

Samples and data from patients with cancer and rare, inherited disorders will be provided by NHS England, working in collaboration with Cancer Research UK and programmes funded by the NIHR and the MRC. Genomics England, a company wholly owned by the Department of Health, will pay for the generation of whole genome sequence data.

Genomics England will pay also for the generation of summary reports, based upon clinical annotations of this data, and will return these to the NHS to support patient care. Genomics England will make anonymised, redacted versions of the data available for industrial research strictly within a secure, managed environment.

The proposed infrastructure will provide a similar environment for academic research, with a more comprehensive collection of genomic and patient data, including the read-level data used for the generation of variant calls and summary reports. The infrastructure will include software tools to support the production of 'research-ready' data sets, the effective management of patient and genomic data, and the delivery of collaborative clinical research.

The project partners have experience in infrastructure development and clinical genomics research, and will be able to re-use designs, procedures, and software developed and tested within existing programmes and organisations, including UK Biobank and the European Bioinformatics Institute.

A formal mechanism will be established for engagement with public, charitable, and philanthropic funders, and with the clinical research projects that they fund. Subject to capacity constraints, projects that add appropriate value to the Genomics England programme will be provided with access to the compute infrastructure at no charge.